SCHEMBL20119863

SCHEMBL20119863

Clc1nc(NCc2ccncc2)c2nc(OC3CCC3)[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.40
KDM4C Q9H3R0 1/20 0.35
PDE5A O76074 2/20 0.33
CDK1 P06493 2/20 0.33
CCNE2 O96020 2/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
PDE8B O95263 1/20 0.33
APP P05067 1/20 0.33
ESR1 P03372 1/20 0.33
NT5E P21589 1/20 0.33
PGK1 P00558 1/20 0.32
CTSL P07711 1/20 0.32
FLT1 P17948 1/20 0.32
KDR P35968 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
YTHDC1 Q96MU7 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119518 0.88 PDE10A (0.37) PDE10APDE5ACDK1CCNE2CCNE1
SCHEMBL20119923 0.85 KDM4C (0.33) KDM4C
SCHEMBL20119458 0.85 KDM4C (0.39) PDE10AKDM4CPDE5ACDK1CCNE2
SCHEMBL20119508 0.83 KDM4C (0.41) PDE10AKDM4CPDE5ACDK1CCNE2
SCHEMBL20119907 0.82 CCNE2 (0.44) PDE10APDE5ACDK1CCNE2CCNE1
SCHEMBL20119910 0.81 PDE10A (0.47) PDE10APDE5ACDK1CCNE1CDK2
SCHEMBL20119804 0.80 HRH4 (0.34)
SCHEMBL20119792 0.80 SMN1; SMN2 (0.46) ADORA2AADORA1
SCHEMBL20119522 0.80 CDK1 (0.40) PDE10AKDM4CPDE5ACDK1CCNE2
SCHEMBL22403782 0.79 PDE10A (0.33) PDE10ANT5EFLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE10A 2441/4885KDM4C 3672/4885PDE5A 3202/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PDE10A 2441/4885KDM4C 3672/4885PDE5A 3202/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE10A 2441/4885KDM4C 3672/4885PDE5A 3202/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 PDE10A 2441/4885KDM4C 3672/4885PDE5A 3202/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 PDE10A 2441/4885KDM4C 3672/4885PDE5A 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.